Lung Disease News and Research

RSS

New study confirms the effectiveness of LDCT screening in a never-smoker high-risk population

A study presented today by researchers with the Ministry of Health and Welfare in Taiwan confirmed the effectiveness of low-dose computed tomography (LDCT) screening in a pre-defined, never-smoker, high-risk population.

31 Jan 2021

County-level sociodemographic risk factors associated with COVID-19 incidence and mortality

In just one year, COVID-19 has killed more than 400,000 Americans, and infected more than 24 million others. But a new study shows just how unevenly those deaths and cases have played out across the country.

29 Jan 2021

Health authorities should develop targeted health messages for vaping products, says researcher

Health authorities should develop targeted health messages for vaping product and e-liquid packaging to encourage smokers to switch from cigarettes to e-cigarettes and to prevent non-smokers from taking up vaping, a researcher at the University of Otago, Wellington, New Zealand says.

27 Jan 2021

Current surgical risk scores overestimate risk in mini-AVR procedures

Minimally invasive aortic valve replacement surgery is a safer procedure than indicated by current surgical risk scores, according to Joseph Lamelas, M.D., chief and program director of cardiothoracic surgery at the University of Miami Health System.

27 Jan 2021

Iron-carrying extracellular vesicles promote viral-bacterial co-infection

The mechanism by which acute viral respiratory infections promote secondary bacterial growth and infection in the airways depends on iron-carrying extracellular sacs secreted by the cells lining the host's airways, report researchers from the University of Pittsburgh School of Medicine in a paper published today in Cell Reports.

26 Jan 2021

Vitamin D deficiency associated with higher risk of COVID-19 hospitalization

A new study published shows that low levels of vitamin D are associated with a higher risk of COVID-19 hospitalization.

21 Jan 2021

Monocytes could be a key player in sarcoidosis pathogenesis, study shows

The cause of the inflammatory lung disease sarcoidosis is unknown.

21 Jan 2021

Age is a key factor in sex-related outcomes after heart attack, indicates study

Approximately 1.5 million heart attacks and strokes occur every year in men and women in the U.S. Sex and age play a large part in who experiences a heart attack, the methods used to treat these heart attacks, and the eventual post hospital outcomes of the people who experience heart attacks.

20 Jan 2021

Researchers receive $5.1 million to expand clinical trial of drug to prevent ARDS in COVID-19 patients

Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress s to expand the Phase II clinical trial at The University of Texas Health Science Center at HoustonQ.

13 Jan 2021

Synthetic lung organoids provide high-throughput platform to identify new cellular targets of SARS-CoV-2

An interesting new study published on the bioRxiv preprint server describes a new platform that allows a high-throughput workflow to generate matched human lung buds in the tens of thousands. This allows researchers to study SARS-CoV-2 infection and therapeutics in lung tissue that mirrors the key aspects of human lung development.

10 Jan 2021

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

7 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

Are SARS-CoV-2 antibodies associated with disease enhancement?

As SARS-CoV-2 continues to wreak its havoc, antibodies that neutralize the virus and protect against infection have become an important focus of research. However, there is a concern as to whether these antibodies can actually enhance the disease.

6 Jan 2021

E-cigarettes, as consumer products, are not associated with smoking cessation

E-cigarette use has risen steeply and mostly without regulation over the past decade. The devices have diversified into a dizzying array of vape pens, tank systems, "mods," and more, mass-marketed and sold to the public.

23 Dec 2020

New therapeutic strategy designed to improve kidney function after lung transplantation

The Covid-19 pandemic shows the importance of medical research in the treatment of lung diseases. The Medical University of Vienna is renowned the world over in the field of lung transplantation medicine.

23 Dec 2020

Scientists discover molecular defects associated with rare genetic disorder in children

Damien D'Amours and his team at the Ottawa Institute of Systems Biology needed three years to discover the molecular defects associated with the LIC Syndrome, a serious genetic disorder that affects young children and result in acute respiratory distress, immune deficiency and abnormal chromosomes.

22 Dec 2020

Cadmium linked to more severe flu and pneumonia infections

In this interview, News-Medical speaks to Dr. Howard Hu about his latest research into cadmium and how it could be causing more severe pneumonia infections.

22 Dec 2020

FDA approves first adjuvant treatment for patients with non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.

18 Dec 2020

CN Bio and University of Melbourne announce partnership focused on respiratory therapies for recovering COVID-19 patients

CN Bio, a leading cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients.